| Date Filed | Type | Description |
| 10/10/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2023 |
SC 13G/A
| Sorrento Therapeutics, Inc. reports a 2.6% stake in CELULARITY INC. |
| 10/05/2023 |
4
| Sorrento Therapeutics, Inc. (10% Owner) has filed a Form 4 on Celularity Inc|
Txns:
| Sold 9,064,539 shares
@ $0
Sold 6,307,158 shares
@ $0 |
|
| 08/25/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/04/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/28/2023 |
8-K
| Quarterly results |
| 07/28/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/19/2023 |
4
| Kilcoyne Adrian (Chief Medical Officer) has filed a Form 4 on Celularity Inc|
Txns:
| Granted 875,000 shares
@ $0 |
|
| 06/30/2023 |
4/A
| Lim Kok Thay (Director) has filed a Form 4 on Celularity Inc|
Txns:
| Paid exercise price by delivering 10,844 shares
@ $0.7503, valued at
$8.1k
|
|
| 06/16/2023 |
4
| Parks Diane L. (Director) has filed a Form 4 on Celularity Inc|
Txns:
| Granted 199,921 shares
@ $0
Granted 277,778 options to buy
@ $0.7503, valued at
$208.4k
|
|
| 06/16/2023 |
4
| Kehler Dean C (Director) has filed a Form 4 on Celularity Inc|
Txns:
| Granted 199,921 shares
@ $0
Granted 277,778 options to buy
@ $0.7503, valued at
$208.4k
|
|
| 06/16/2023 |
4
| Smith Robin L (Director) has filed a Form 4 on Celularity Inc|
Txns:
| Granted 199,921 shares
@ $0
Granted 277,778 options to buy
@ $0.7503, valued at
$208.4k
|
|
| 06/16/2023 |
4
| Mazur Marc (Director) has filed a Form 4 on Celularity Inc|
Txns:
| Granted 199,921 shares
@ $0
Granted 277,778 options to buy
@ $0.7503, valued at
$208.4k
|
|
| 06/16/2023 |
4
| VON ESCHENBACH ANDREW C. (Director) has filed a Form 4 on Celularity Inc|
Txns:
| Granted 199,921 shares
@ $0
Granted 277,778 options to buy
@ $0.7503, valued at
$208.4k
|
|
| 06/16/2023 |
4
| SCULLEY JOHN (Director) has filed a Form 4 on Celularity Inc|
Txns:
| Granted 199,921 shares
@ $0
Granted 277,778 options to buy
@ $0.7503, valued at
$208.4k
|
|
| 06/16/2023 |
4
| Diamandis Peter (Director) has filed a Form 4 on Celularity Inc|
Txns:
| Granted 199,921 shares
@ $0
Granted 277,778 options to buy
@ $0.7503, valued at
$208.4k
|
|
| 06/16/2023 |
4
| Lim Kok Thay (Director) has filed a Form 4 on Celularity Inc|
Txns:
| Granted 199,921 shares
@ $0
Granted 277,778 options to buy
@ $0.7503, valued at
$208.4k
|
|
| 06/16/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 06/02/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/31/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/25/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/19/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office...|
Docs:
|
"ARTICLE I.",
"FORM OF COMMON STOCK PURCHASE WARRANT Celularity Inc. Warrant Shares: [ ] Issue Date: May 18, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, [ ] or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after May 18, 2023 and on or prior to 5:00 p.m. on May 18, 2028 , but not thereafter, to subscribe for and purchase from Celularity Inc., a Delaware corporation , up to [ ] shares of Class A common stock, par value $0.0001 per share . The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth i...",
"REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement is made and entered into as of May 18, 2023, between Celularity Inc., a Delaware corporation , and each of the several Holders signatory hereto. This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date thereof, between the Company and each Purchaser party thereto . The Company and each Holder hereby agree as follows: 1. Definitions. Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings: “Advice” shall have the meaning set forth in Section 6. “Effectiveness Date” means, with ..." |
|
| 05/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/27/2023 |
8-K
| Quarterly results |
| 04/21/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|